Posts by admin
Latest Market Research Report on Stem Cell Research in Cardiology
BrandPrinciples.com has been working on various market research reports pertaining to biotechnology which is their expertise and thus, concentrate only on this industry which is growing at a high speed. These unique research reports are of immense value to investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools.
This report specifies the importance of Stem Cell Research in Cardiology. The study is segmented by Source (Allogenic and Autogenic) and by Type (Bone Marrow Stem Cells, Embryonic Stem Cells, and Other). Projections and estimates are graphically illustrated by geographic region encompassing North America, Europe, Asia-Pacific, and Rest of World. Business profiles of 23 major companies are discussed in the report. The report serves as a guide to global market for Stem Cell Research in Cardiology covering 229 companies that are engaged in stem cell R&D, storage, banking, discovery, testing and supply of products and services. Major Contract Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Exhibits (27) complement the text.
Heart disease has assumed great magnitude as an endemic health problem. Cardiology field has seen significant efforts in clinical research in the past few years with the development of new drugs and surgical modalities of therapy as well. However, the mortality rates remain very high. In this context, stem cell applications in cardiology assume great significance since stem cells have been found to be successfully used in tissue regeneration. Heart disease, including myocardial infarction and ischemia, can be treated with the applications of stem cells.
The concept of stem cell transplantation to regenerate the myocardium and better the working of the heart has received a great deal of attention in recent times. Small-scale studies in the pre-clinical and clinical stages support the use of stem cells in treating heart disease. However similar such studies must be carried out on a larger-scale to corroborate the findings and prove stem cell therapy as a viable alternative method of treating patients with heart disease.
The global market for Stem Cells in Cardiology is projected to reach about US$ 3.5 billion by 2012. Adult stem cells market is the largest tapped market while cord blood and embryonic stem cell markets, though with huge market potential, are still in infancy stages. Embryonic stem cells to treat cardiac disorders is a very interesting area of research. However, due to various ethical issues, this area is mired in debates all over the world.
A free sample of report is available on request sent through their website – Stem Cell Research in Cardiology.
Cell-Based Assays For Drug Discovery—-Aarkstore Enterprise
The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers’ original equipment manufacturer (OEM) additional equipment.
Table of Contents :
1. Overview 4
1.1 Objectives of the Report 4
1.2 Methodology 5
1.3 Scope of the Report 6
1.4 Executive Summary 7
2. Technologies and Product Offering for High-Content Analysis 10
2.1 Definition of High-Content Analysis and Why it is so Attractive a Discipline 11
2.2 Classes of Measurements Possible with High-Content Analysis Approaches and Biologies Interrogated 14
2.3 Instrumentation Platforms for High-Content Analysis 17
2.3.1 High-Content Screening Technology 17
2.4 Reagent and Assay Platforms for High-Content Analysis 24
2.5 Cell-based Screening Technologies in Drug Development 28
2.5.1 Applications of Cell-based Assays 28
2.5.2 Pharma Drug Discovery Paradigm and Compound Screening 28
2.5.3 High-Content Analysis in the Biopharmaceutical Industry 29
For more information please contact :
http://www.aarkstore.com/reports/Cell-Based-Assays-for-Drug-Discovery-6634.html
blogs.aarkstore.com/
From: Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
Pushpanjali
Marketing Manager
contact@aarkstore.com
http://www.aarkstore.com
http://blogs.aarkstore.com
Arrowhead Research Corporation (NASDAQ: ARWR) $107M (MarketCap) Receives Grant from the State of Texas
The ETF, created by the Texas Legislature at the urging of Governor Rick Perry, provides Texas with an unparalleled advantage by expediting the development and commercialization of new technologies, to recruit the best research talent in the world and create economic growth and stability. Matching and commercialization funds coupled with additional federal and outside investments mean new technology is emerging in Texas.
The Emerging Technology Fund was created by the Texas Legislature at the urging of Governor Rick Perry to provide the state with investments to foster, develop, and commercialize new technology companies, attracting talent and jobs to the region in the process. The fund offers research superiority awards, matching grant awards, and commercialization awards to applicants who demonstrate innovative case studies and are developing some variation of bio-chemical technology to research centers, universities, and organizations throughout Texas. Companies who have received these awards go on to achieve greater breakthroughs and financial traction; everything from public offerings, to venture capital, to outright buy-outs and clinical trial funding.
Arrowhead Research Corporation is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of the clinical application of RNAi delivery technology.
Arrowhead also has minority investments in two privately held nanobiotech companies, one of which is Leonardo Biosystems. Leonardo is a drug delivery company built around technology developed by Dr. Mauro Ferrari, one of the world’s best-known nano-science innovators and has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs.
The Texas ETF has made an early-stage investment in Leonardo, a new technology-based, private entrepreneurial entity that collaborates with public and private institutions of higher education in Texas. The fund has provided the company with $2.5M, and while Dr. Bruce Given, Leonardo’s chief executive officer has not provided details with how the funds will be used, he did say “this award from the ETF allows us to keep this crucial technology in Texas, where we hope to develop it to its full potential.”
Ultimately, Arrowhead benefits from this milestone as well. By providing strategic management, financing, and operational services to its subsidiaries, Arrowhead takes an active role in their development, allowing the business and technical development teams at the subsidiary companies to remain focused on near term revenue opportunities and capital efficiency. Arrowhead’s ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company or could retain ownership of its subsidiary to capture its continuing cash flow and income.
Currently, Arrowhead owns about 6.13% of the outstanding shares of Leonardo; about 70% of the outstanding shares of Calando Pharmaceuticals, Inc.; about 80% of the outstanding shares of Unidym, Inc.; a minority interest in Agonn Systems, a nanotech based energy device maker; and a minority interest in Nanotope, Inc., an advanced nanomaterials developer for the treatment of spinal cord injuries and would healing.
To view this article at World Market Media click on the link below: http://www.worldmarketmedia.com/779/section.aspx/1764/post/arrowhead-research-corporation-nasdaq-arwr-107m-marketcap-receives-grant-from-the-state-of-texas
Disclosure: no positions
About World Market Media:
WorldMarketMedia.com (The Global Online Investment Community) is a high traffic stock market, news data website providing cutting edge new media products and services to publicly traded companies worldwide. Our Editor’s Desk authors insightful real-time coverage on the economy, the capital markets and their listed companies.
MedImmune: collaboration with Trellis strengthens RSV pipeline
MedImmune: collaboration with Trellis strengthens RSV pipeline
MedImmune has agreed to license the rights to develop Trellis Bioscience’s monoclonal antibody products for the treatment of respiratory syncytial virus (RSV). MedImmune already has one RSV product on the market and has filed for motavizumab, its follow-on compound. However, the efficacy of both products can be improved upon, which may have driven MedImmune’s decision to collaborate with Trellis. ( http://www.bharatbook.com/detail.asp?id=124900&rt=Monoclonal-antibodies-2009-update.html )
Trellis Bioscience has granted a worldwide exclusive license to MedImmune, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV). The RSV antibodies were discovered using Trellis’ proprietary CellSpot discovery platform which enables rapid identification and isolation of human antibodies produced from the B-cells of RSV-infected patients. The deal’s value could reach $338 million if a product reaches the market.
MedImmune already has one marketed RSV antibody product (Synagis; palivizumab), which is currently the only available drug for prophylaxis of RSV infection. Synagis was approved in June 1998 for the prevention of serious respiratory disease caused by RSV in infants and children with a history of preterm birth (less than or equal to 35 weeks’ gestation) or chronic liver disease (CLD). While it has successfully reduced RSV hospitalizations in this high risk population, its clinical efficacy can still be improved upon.
Recognizing Synagis’ shortcomings, MedImmune developed a follow-on compound, motavizumab. This antibody has to-date demonstrated non-inferiority to Synagis but does not offer any significant improvements in terms of efficacy. The company filed for approval of motavizumab in January 2008 but received a Complete Response Letter (CRL) from the FDA asking for additional information. It is yet unclear whether MedImmune has addressed the regulator’s questions.
In addition to motavizumab, the company is also developing an extended half-life RSV monoclonal antibody, two vaccines for RSV prophylaxis and an F-protein inhibitor for the treatment of RSV infection. MedImmune’s collaboration with Trellis comes as a logical step considering the attractive market gap for RSV therapies with improved efficacy.
Given that motavizumab does not offer any significant therapeutic benefits over Synagis and the extended release version will only offer improvements in terms of administration, it is likely that MedImmune will develop Trellis’ RSV antibodies as successors to motavizumab and may also use them in combination with other RSV products. Other companies with RSV products in development include Pevion Biotech which has an RSV vaccine in preclinical stages, and Cubist Pharmaceuticals which is developing Alnylam’s RNAi-based RSV inhibitors.
Related research
• Monoclonal antibodies: 2009 update
http://www.bharatbook.com/detail.asp?id=124900&rt=Monoclonal-antibodies-2009-update.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: twitter.com/3bbharatbook
Bharat Book Bureau, the leading market research information aggregator provides reports, company profiles, newsletters, country info. and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our reports help global companies to know different market before starting up business / expanding in different countries across the world.
Aarkstore Enterprise- Cell-Based Assays for Drug Discovery-Biotechnology, Healthcare and Life Market Research Reports
Table of Contents :
1. Overview 4
1.1 Objectives of the Report 4
1.2 Methodology 5
1.3 Scope of the Report 6
1.4 Executive Summary 7
2. Technologies and Product Offering for High-Content Analysis 10
2.1 Definition of High-Content Analysis and Why it is so Attractive a Discipline 11
2.2 Classes of Measurements Possible with High-Content Analysis Approaches and Biologies Interrogated 14
2.3 Instrumentation Platforms for High-Content Analysis 17
2.3.1 High-Content Screening Technology 17
2.4 Reagent and Assay Platforms for High-Content Analysis 24
2.5 Cell-based Screening Technologies in Drug Development 28
2.5.1 Applications of Cell-based Assays 28
2.5.2 Pharma Drug Discovery Paradigm and Compound Screening 28
2.5.3 High-Content Analysis in the Biopharmaceutical Industry 29
3. Market Analysis of the High-Content Tools Space 31
3.1 High-Content Analysis Market Size and Growth 31
3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the High-Content Analysis Space 31
3.3 Experimental and Research Trends in High-Content Analysis 33
3.4 Challenges and Market Drivers in High-Content Analysis 38
3.4.1 Barriers to High-Content Analysis 40
3.4.2 Drivers of High-Content Analysis 41
3.5 High-Content Analysis in Combination with RNAi 41
3.6 Market Landscape of Instrumentation for High-Content Analysis 43
3.7 Reagents and Assays Usage in High-Content Analysis 47
3.8 Trends in High-Content Analysis Assays/Reagents Space-Major Product Vendors 50
3.9 Emerging Market Trends in High-Content Analysis 52
3.10 Market Forecasts for the High-Content Analysis Space 54
3.11 Use of HCS in Pharmaceutical Companies 56
3.12 Qualitative Opportunities and Challenges for Market Adoption 57
Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether youre looking for new product trends or competitive analysis of a new or existing market, Aarkstore Enterprise has the best resource offerings and the expertise to make sure you get the right product every time.
For more information please contact :
http://www.aarkstore.com/reports/Cell-Based-Assays-for-Drug-Discovery-6634.html
blogs.aarkstore.com/
From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com